Board summary
Key figures
61,403
Registered population
55.7% aged 18–64
23.2%
Aged 65+
ICB 18.8% · England 17.9%
6.2%
Ethnic minority (non-White)
2.6% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 0.8% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
9,667
Hypertension register
+5.11% in 3 yrs · England +5.60%
503
SMI register
38.3% of Waverley's
784
COPD register
Reviews +11.39% in 3 yrs
Forecast to 2030
11,269
Hypertension patients, 2030
+1,602 on today
69.5%
QRISK ≥20% on statins, 2030
+6.39pp over 3 yrs
6.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Lipid therapy trails England across high-risk cohorts.
CKD lipid-lowering therapy is 57.5% (England 70.3%) and QRISK ≥ 20% is 54.1% (England 63.6%), which may reflect unverified recall gaps.
Learning disability register fell; SMI checks trail.
The 284-patient learning disability register fell by 18.6% over 2023 to 2025 (England +5.4%), while SMI blood pressure checks are 77.6% (England 83.4%).
Blood pressure control under 80 outpaced England.
Control under 80 rose +12.8% over 2023 to 2025 (England +3.2%), and overall hypertension treatment to target rose +6.8 pp to 68.2%.
Population, age and ethnicity
Older residents comprise 23.2% of registered patients, exceeding England by 5.3 percentage points
East Waverley PCN serves 61,403 registered patients with an older age profile: 23.2% (14,267) are aged 65+, above Waverley (22.0%), NHS Surrey Heartlands Integrated Care Board (18.8%) and England (17.9%). Children aged 0-17 represent 21.1% (12,945). In associated Census areas, 93.8% of residents identify as White (Waverley 93.6%, ICB 85.3%, England 81.1%) and 2.6% as Asian (Waverley 2.8%, ICB 7.7%, England 9.6%). Projected list growth of 4.4% to 2030 (England 2.3%) may increase demand for complex chronic disease management, although the projection methodology remains unverified and Census ethnicity does not record patient-level registration.
Age profile
65+: ICB 18.8%, England 17.9%
Ethnicity
Older people · falls rows are Waverley local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Waverley LA) | 2,164 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 82.7% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 62.2% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Waverley LA) | 912 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Waverley LA) | 9.6 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Average IMD decile is 8.3 with 0.0% of registered patients in Core20 areas
East Waverley PCN has an average IMD decile of 8.3, compared with 8.5 in Waverley, 7.9 in NHS Surrey Heartlands Integrated Care Board, and 5.5 in England. Across all practices, 0.0% of registered patients live in Core20 areas, matching Waverley (0.0%) and below NHS Surrey Heartlands Integrated Care Board (0.8%) and England (21.0%), with 0 estimated resident patients in deciles 1 and 2. The absence of Core20 areas suggests health inequality initiatives could prioritize clinical risk registers and inclusion groups over area-based targeting.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
503
SMI register
0.81% recorded prevalence
284
Learning disability register
0.46% recorded prevalence
26
Care homes, 1,319 beds
In the PCN catchment
7.8%
Provide unpaid care
Waverley, Census 2021
The PCN records 284 patients on the learning disability register (0.5%, England 0.6%) and 503 on the severe mental illness register (0.8%, England 1.0%), alongside 26 catchment care homes with 1,319 beds. At borough level, autumn 2025 snapshot data records 4 people sleeping rough, alongside an estimated PCN ceiling of 4,789 unpaid carers.
Severe mental illness: physical health checks
Across the 503-patient severe mental illness register (0.8% vs England 1.0%), blood pressure checks (77.6% vs 83.4%; Cranleigh Medical Practice 68.4%), BMI recording (77.6% vs 82.1%), and alcohol recording (69.9% vs 81.8%) trail England.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
9,667
Hypertension register
+5.11%
Register growth, 3 yrs
Waverley +6.01% · England +5.60%
+7.28pp
BP control, under 80
≤140/90 · +6.20pp aged 80+
+1,602
More patients by 2030
Forecast 11,269 (17.28%)
Hypertension case-finding and control
Hypertension prevalence is 15.6% (9,667 patients), compared with Waverley (15.4%), NHS Surrey Heartlands Integrated Care Board (14.3%) and England (15.2%). Over 2023 to 2025, patients treated to target rose +6.8 pp (+11.0%, England +2.5 pp, +3.6%) to 68.2% (England 70.3%). However, blood pressure control among patients aged under 80 is 64.0%, trailing England (67.8%), Waverley (65.3%) and NHS Surrey Heartlands Integrated Care Board (68.1%). Recent blood pressure readings were recorded for 88.1% of patients (England 90.0%).
Lipids and statins
Lipid-lowering therapy coverage trails comparators across primary prevention: 54.1% for QRISK ≥ 20% (England 63.6%), 57.5% for chronic kidney disease (England 70.3%) and 65.7% for diabetes without CVD (England 73.2%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 74,325 | £2.40 | £2.24 | £1.86 | £178,380 |
| Cardiovascular (all), 2025 | 116,690 | £5.59 | £4.74 | £3.33 | £652,297 |
In 2026, lipid-regulating drugs cost £2.40 per item across 74,325 prescribed items (£178,380 spend), exceeding Waverley (£2.12), NHS Surrey Heartlands Integrated Care Board (£2.24) and England (£1.86), representing £40,136 more than at England's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+10.99%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+2.86%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.0% (4,047 patients, England 6.6%), while 12-month review coverage is 60.5% (England 65.7%), leaving about 1,600 patients without a recorded review. For patients aged 6 to 19 with asthma, second-hand smoke recording is 71.8% (England 78.8%). COPD prevalence is 1.3% (784 patients, England 1.9%) with annual reviews at 74.1% (England 76.4%).
Cancer register and children's immunisation
The cancer register records 3,228 patients (5.2% vs England 3.8%). In Q1 2025/26, 6-in-1 coverage at 12 months was 93.5% and MMR dose 1 at 24 months was 93.6%, both below the 95.0% target. At age 5, MMR dose 2 reached 94.7%, trailing dose 1 (96.0%) by 1.3 pp.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
61.4%
Surrey Heartlands ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~650
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Surrey Heartlands ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 65.7% | 53.2% | 18% | 1,044 |
| Breast | 88.2% | 85.4% | 27% | 798 |
| Bowel | 48.1% | 47.0% | 18% | 626 |
| Lung | 33.2% | 33.8% | 17% | 497 |
| Skin cancer | 89.8% | 87.8% | 19% | 384 |
In 2022, 61.4% of cancers with a known stage in NHS Surrey Heartlands ICB were diagnosed at stage 1 or 2 (2,955 of 4,810 staged cases), exceeding England's 55.3% but sitting 13.6 pp below the 75.0% national ambition by 2028, requiring about 650 extra early-stage diagnoses yearly (652.5). Staging completeness was 67.7% (4,810 of 7,106 registered cancers; England 67.0%). Early diagnosis was 88.2% for breast and 76.7% for cervix, but 48.1% for bowel and 33.2% for lung. At PCN level, cervical screening coverage is 73.9% (England 66.8%), while Cranleigh Medical Practice recorded 70.0% against Waverley's 73.8%.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), Royal Surrey NHS Foundation Trust met the 28-day faster diagnosis standard at 82.6% (standard 75.0%) and the 31-day combined standard at 96.4% (standard 96.0%). On the 62-day standard, Royal Surrey achieved 84.5%, sitting 0.5 pp below the 85.0% standard, while exceeding Frimley Health NHS Foundation Trust (81.8%), Ashford and St Peter's Hospitals NHS Foundation Trust (76.4%), NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%). In Jul 2026, Royal Surrey 6-week diagnostic waits were 0.0% for MRI, 0.1% for CT, 0.1% for non-obstetric ultrasound, and 38.5% for urodynamics.
| Pathways within standard (%) | Royal Surrey | Frimley Health | Ashford and St Peter's | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 82.62 | 87.95 | 85.53 | 79.29 | 79.32 |
| 31-day treatment (96%) | 96.43 | 92.89 | 94.21 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 84.48 | 81.84 | 76.38 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Royal Surrey | Frimley Health | Ashford and St Peter's | England |
|---|---|---|---|---|
| MRI | 0.00 | 12.85 | 0.09 | 21.40 |
| CT | 0.15 | 0.63 | 9.27 | 9.92 |
| Echocardiography | 1.55 | 3.35 | 0.97 | 28.48 |
| Colonoscopy | 0.00 | 22.84 | 49.61 | 30.83 |
| Gastroscopy | 0.00 | 7.43 | 56.74 | 29.02 |
| All 15 DM01 tests | 8.82 | 7.49 | 23.12 | 23.14 |
| Community services activity | Surrey residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 109,530 | 309,615 |
| Referrals | 28,700 | 66,930 |
| Patients with a contact | 33,510 | 85,660 |
Community services (residents of Surrey), Jun 2026 (provisional). In Jun 2026 (provisional), community health service activity recorded 109,530 contacts for Waverley residents, of which 76,215 (69.6%) were with adults aged 65+. These borough-level figures reflect wider system activity and are not available at PCN level.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Wonersh Surgery | 131 | 0.0 | 75.7% | 77.6% | 91.8% |
| Binscombe | 104 | 0.0 | 62.2% | 67.7% | 88.3% |
| Mill Medical | 96 | 0.0 | 70.1% | 88.3% | 84.1% |
| Cranleigh Medical | 106 | 0.0 | 75.5% | 71.2% | 80.2% |
| Springfield | 127 | 0.0 | 54.8% | 77.5% | 73.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Learning disability prevalence fell 18.6% while blood pressure control rose +12.8%
Over 2023 to 2025, learning disability prevalence fell 18.6% (Waverley +6.5%, NHS Surrey Heartlands ICB +8.2%, England +5.4%), 24.0 points behind England, and heart failure reviews fell 3.8% (Waverley +2.6%, NHS Surrey Heartlands ICB +0.7%, England +8.7%). Dementia prevalence fell 0.1% (Waverley +4.5%, NHS Surrey Heartlands ICB +5.7%, England +6.0%). Conversely, blood pressure control under 80 rose +12.8% (Waverley +4.6%, NHS Surrey Heartlands ICB +3.8%, England +3.2%) and COPD reviews rose +11.4% (Waverley +6.8%, NHS Surrey Heartlands ICB +0.3%, England +2.8%). Register declines could reflect unverified coding adjustments, which clinical audits could test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
Heart failure reviews
Dementia register
Breast screening (53-70)
Smoking support (SMI)
BP control, under 80
COPD reviews
Hypertension treated to target
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Waverley | Asset | PCN | Waverley |
|---|---|---|---|---|---|
| Care homes (catchment) | 26 (1,319 beds) | n/a | Schools (catchment) | 79 | n/a |
| Children's centres | 5 | 7 | Places of worship | 67 | 95 |
| Libraries | 3 | 4 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | 2 | 2 | Children and young people (VCS) | 1 | 1 |
| Carers support groups (VCS) | 1 | 1 | Primary schools (LA maintained) | 9 | 18 |
| Primary academies | 12 | 17 | Special schools | 2 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Primary prevention lipid recall and review
Lipid therapy is below England for CKD (57.5% vs 70.3%, difference -12.8 percentage points), QRISK ≥ 20% (54.1% vs 63.6%, difference -9.5 percentage points), diabetes without CVD (65.7% vs 73.2%, difference -7.4 percentage points) and with CVD (78.1% vs 84.4%, difference -6.3 percentage points); patient gap not sized. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Learning disability register coding validation
The 284-patient learning disability register (0.5% vs England 0.6%) fell 18.6% over 2023 to 2025 (England +5.4%), giving an unadjusted benchmark gap range of +38 to +77 across 61,403 patients. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Option 3
SMI physical health check outreach
On the 503-patient SMI register (0.8% vs England 1.0%), annual BP checks are 77.6% (England 83.4%; Cranleigh Medical Practice 68.4%), BMI 77.6% (82.1%) and alcohol 69.9% (81.8%); gap not sized. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older population capacity planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Systematic SMI physical health recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension control review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation call-recall review (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Primary prevention lipid recall and review (p12) | Hypertension register · CKD patients treated with lipid lowering therapy · Patients with QRISK ≥ 20% treated with lipid lowering therapy | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · Learning disability register coding validation (p12) | Learning disability register · Learning disability: QOF prevalence · Registered population | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Option 3 · SMI physical health check outreach (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
